Back
Prostate MRI based on PI-RADS version 2: how we review and report.
Journal article

Prostate MRI based on PI-RADS version 2: how we review and report.

  • Steiger P Department of Radiology, Neuroradiology, and Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, CH-3010, Bern, Switzerland. Philipp.Steiger@med.unibe.ch.
  • Thoeny HC Department of Radiology, Neuroradiology, and Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, CH-3010, Bern, Switzerland.
  • 2016-04-13
Published in:
  • Cancer imaging : the official publication of the International Cancer Imaging Society. - 2016
Multiparametric magnetic resonance imaging (mpMRI)
Prostate Imaging Reporting and Data System version 2 (PI-RADS™ v2)
Prostate cancer
Communication
Contrast Media
Data Display
Diffusion Magnetic Resonance Imaging
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Humans
Image Enhancement
Image Interpretation, Computer-Assisted
Interprofessional Relations
Magnetic Resonance Imaging
Male
Neoplasm Recurrence, Local
Prostate
Prostatic Hyperplasia
Prostatic Neoplasms
Radiology Information Systems
English Prostate imaging and interpretation is based on prostate imaging reporting and data system version 2 (PI-RADS™ v2) providing clinical guidelines for multiparametric magnetic resonance imaging (mpMRI) of the prostate. PI-RADS™ v2 aims to promote global standardisation, to diminish variation in the acquisition, interpretation and reporting of prostate mpMRI examinations and to improve detection, localisation, and risk stratification in patients with suspected cancer in treatment naïve prostate glands. It does not address detection of recurrence, progression during active surveillance and evaluation of other parts of the body.PI-RADS™ v2 improves and standardises communication between radiologists and urologists to detect or exclude the presence of significant prostate cancer with a high likelihood. Findings on mpMRI are assessed on a 5-point category scale based on the probability that a combination of findings on T2-weighted (T2w) sequences, diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) correlates with the presence of a clinically significant prostate cancer at a particular location. PI-RADS assessment categories range from 1 to 5 with 5 being most likely to represent clinically significant prostate cancer. The dominant sequence to detect prostate cancer in the peripheral zone is DWI, whereas for tumour detection in the transition zone T2w is the most important sequence. DCE-MRI has been attributed a minor role and only qualitative assessment with presence or absence of focal enhancement is suggested. Up to four suspicious lesions of category 3, 4 and 5 are assigned on a sector map and the index lesion should be identified.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/233029
Statistics
Document views: 9 File downloads: